Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 11/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 8/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20620105 | 0.91 | AVPR2 (0.39) | AVPR2AVPR1AADORA2AADORA1CHRNA7 | |
| SCHEMBL20622339 | 0.91 | AVPR2 (0.42) | AVPR2AVPR1AADORA2AALDH1A1 | |
| SCHEMBL20620181 | 0.91 | AVPR2 (0.41) | AVPR2AVPR1A | |
| SCHEMBL20619707 | 0.91 | AVPR2 (0.42) | AVPR2AVPR1A | |
| SCHEMBL20619925 | 0.91 | AVPR2 (0.39) | AVPR2AVPR1ACHRNA7 | |
| SCHEMBL20620080 | 0.91 | AVPR2 (0.40) | AVPR2AVPR1ACHRNA7 | |
| SCHEMBL20622334 | 0.90 | AVPR2 (0.39) | AVPR2AVPR1ACHRNA7 | |
| SCHEMBL20619859 | 0.90 | AVPR2 (0.41) | AVPR2AVPR1A | |
| SCHEMBL20619870 | 0.90 | AVPR2 (0.39) | AVPR2AVPR1ACHRNA7 | |
| SCHEMBL20619508 | 0.90 | AVPR2 (0.41) | AVPR2AVPR1AADORA2AADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091501-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | AVPR2 1011/4885L3MBTL1 4774/4885AVPR1A 1410/4885 |
| US-20190002479-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | AVPR2 1011/4885L3MBTL1 4774/4885AVPR1A 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.